Announcement on the 2020 profit distribution plan.
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Pro 2021-007
Zhejiang Jianfeng Group Co., Ltd.
Announcement on 2020 Profit Distribution Plan
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Content Note:
- Distribution Ratio per Share: Cash Dividend 4.0 Yuan (Including Tax) for Every 10 Shares. No bonus shares will be distributed in 2020, and no CPF capitalization will be carried out.
- This profit distribution is based on the total share capital registered on the equity registration date of the implementation of the equity distribution, and the specific date will be specified in the equity distribution implementation announcement.
- If the total share capital of the company changes before the equity registration date for the implementation of the equity distribution, it is proposed to maintain the distribution ratio per share unchanged and adjust the total distribution accordingly, and the specific adjustment will be announced separately.
- Brief description of this year's profit distribution plan: At present, the company is in the stage of accelerated development. In 2021, the company will continue to promote the peak pharmaceutical Jinxi production base annual output of 2 billion pieces of solid preparations project. In addition, Spike Pharmaceuticals and its subsidiaries have a number of new drugs in various stages of research and development, anti-tumor new drugs DPT and JFAN-1001 have entered the clinical stage, Spike Pharmaceuticals and its subsidiaries Zhejiang Erying, Spike Yien will further increase product research and development and introduction efforts, the need to increase investment in research and development. In addition, the company will continue to seek other development projects in cement and medicine. The development of the above-mentioned business requires large financial support.
Content of 1. Profit Distribution Plan
Audited by Tianjian Certified Public Accountants (Special General Partnership), the net profit attributable to shareholders of the parent company in the consolidated statement of the company in 2020 was ,584,420, 195.33 yuan; The net profit of the parent company's accounting statement 421,557,349.00 yuan. According to the parent company's current net profit as the base, extract 10% statutory provident fund 42,155,734.90 yuan, plus undistributed profit 1,152,229,187.97 yuan at the beginning of the year, minus 2019 annual cash dividend 103,225,148.40 yuan, and the distributable profit for this year is 1,428,405,653.67 yuan.
Company plans to make cash distribution in 2020 . Based on 2020 year-end share capital 344,083,828 shares, cash dividend 4.0 yuan (tax included) will be distributed for every 10 shares, and the total cash dividend will be distributed to all shareholders registered on the equity registration date is 137,633,531.20 yuan (tax included).
2020 No provident fund conversion to share capital.
If the total share capital of the company changes due to the conversion of convertible bonds/ repurchase of shares / equity incentive grant of share repurchase and cancellation / major asset restructuring share repurchase and cancellation during the period from the date of disclosure of this announcement to the date of registration of equity distribution, the company plans to maintain the distribution ratio per share unchanged and adjust the total distribution accordingly. If the subsequent total share capital changes, the specific adjustment will be announced separately.
This profit distribution plan still needs to be submitted to the general meeting of shareholders for consideration. In order to take into account the short-term income of shareholders and the long-term development of the company and maintain the continuity and relative stability of dividends, the board of directors put forward the above-mentioned profit distribution plan for 2020
. During the reporting period, the net profit attributable to shareholders of the listed company in the consolidated statement of the company was584,420,195.33
yuan, and the total cash dividend to be distributed was137,633,531.20 yuan (including tax), accounting for 23.55% of the net profit attributable to shareholders of listed companies this year, lower than 30% . The specific reasons are as follows: At present, the company is in the stage of accelerated development. In 2021 , the company will continue to promote the annual output of 20
.2 billion solid preparation project in Jinxi production base of peak pharmaceutical industry. New Peak North Carolina (formerly Anhui Zhongwang) Phase II Technological Transformation Project; The construction and transformation of projects under construction such as the New North Card Chemical Technology Transformation Project. In addition, Spike Pharmaceuticals and its subsidiaries have a number of new drugs in various stages of research and development, anti-tumor drugsDPT and JFAN-1001 have entered the clinical stage, Spike Pharmaceuticals and its subsidiaries Zhejiang Erying, Spike Yien will further increase product research and development and introduction efforts, the need to increase investment in research and development. In addition, the company will continue to seek other development projects in cement and medicine. The development of the above-mentioned business requires large financial support. 3. the decision-making procedure performed by the company (I) the convening, deliberation and voting of the board meeting
2021
# April24
, the company held the 108 meeting of the 11th board of directors#. the company currently has nine directors, all of whom attended the meeting, comply with the relevant provisions of the "Company Law" and the "Articles of Association", and the resolutions made are legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, the profit distribution plan of the company 2020 was deliberated and approved by 110 votes, 0 votes against, and 0 votes abstention. The board of directors of intends to submit the plan to the annual general meeting of shareholders of 2020 for deliberation. When the company holds the general meeting of shareholders, it will provide investors with convenient conditions for online voting. (II) Opinions of Independent Directors
Independent Directors of the Company express the following opinions on the profit distribution plan of the Company2020 :
1
. We agree that the Company will distribute cash dividends4.0 yuan (including tax) for every 10 shares of the Company
2020year-end share capital ,344,083, 828 shares as the base, the total amount of cash dividends distributed to all shareholders registered on the date of record is ,633,531.20 yuan (including tax). 2020 year will not carry out provident fund to increase the share capital. 2 , the profit distribution plan is based on the actual operating results and financial situation of the company 2020 , combined with the actual needs of the company's future business development. Retained undistributed profits are mainly used to meet the capital needs of the company's development, which is conducive to the sustainable and healthy development of the company, and there is no harm to the rights and interests of shareholders, especially small and medium shareholders. The independent directors are of the opinion that the profit distribution plan complies with the relevant provisions of the Articles of Association for profit distribution and the actual operating conditions of the Company. 3
, the company's board of directors considered and approved the above profit distribution plan. The Independent Directors are of the opinion that the convening, holding and deliberation and voting procedures of this meeting are in compliance with relevant laws, regulations and the Articles of Association of the Company, and are legal and effective; and agree to submit the proposal to the Company's2020 Annual General Meeting for consideration. (III) the opinions of the board of supervisors
2021 July
24, the company held the 161 meeting of the 10th board of supervisors
2#. the company currently has five supervisors, all of whom attended the meeting in person, in line with the relevant provisions of the company law and the articles of association of the company, and the resolution made is legal and valid. The meeting was presided over by Mr. Chen Tianci, Chairman of the Board of Supervisors. After deliberation and voting, the company's profit distribution plan for the year2020 was deliberated and approved by 5 votes, 0 votes against, and 0 abstentions. Agree to submit to the general meeting of shareholders for consideration. The Board of Supervisors believes that: the company's 2020 profit distribution plan complies with the relevant provisions of the Articles of Association; the description of the profit distribution plan is objective and true, the decision-making procedures are in compliance, and meet the interests of all shareholders and the company's production and operation needs; The company's profit distribution and cash dividend decisions were not found to damage the legitimate rights and interests of shareholders. 4. Related Risk Reminder This profit distribution plan must be submitted to the company's 2020
annual general meeting for deliberation and approval before implementation. Investors are kindly requested to pay attention to investment risks.hereby announce
Zhejiang Jianfeng Group Co., Ltd.Dong
Affairs
MeetingApril
27, 2001
More information
Jingmai Airport Test Flight Successfully Runway Cement Spike Manufacturing
On April 7, a Boeing 737-700 aircraft of China Eastern Airlines Yunnan took off from Kunming. After completing two flight test subjects, it landed safely at Lancang Jingmai Airport. This not only marked the basic completion of the airport flight area, The official start of the test flight also marked that the "Peak" brand airport runway cement passed the first "final exam". Lancang Jingmai Airport is a major project with milestone significance in the history of Pu'er transportation construction. Since then, an air corridor connecting southwest Yunnan and Southeast Asia has been added between Kunming and Pu'er, which will greatly promote the development and utilization of tourism resources in Lancang, Menglian and Ximeng "Pu'er Green Triangle" area, and promote the sustainable development of local economy and society; it is of great significance to strengthen the city's national defense construction, maintain border stability, promote national unity, improve emergency rescue capabilities, and promote Pu'er's integration into the country's "Belt and Road" construction. Since the start of the construction of the airport, Yunnan Jianfeng has been paying close attention to it, organizing technical research and repeated tests, and finally produced high-quality airport runway special cement, and with excellent product quality, superior product performance and high-quality service, it has become a runway for Lancang Airport. Cement manufacturer. This not only fills the gap of "peak" airport special cement, but also is of great significance to promote the "peak" brand and improve the market influence of enterprises. It is understood that Jingmai Airport is initially confirmed to be officially opened to traffic at the end of May. (Li Liangping)
2020
07-31
Jianfeng Pharmaceutical Artificial Niuhuang Project Starts
News from this newspaper Jianfeng Pharmaceutical artificial bezoar technical transformation project recently started construction in Qiubin Factory. Artificial bezoar has the effect of clearing away heat and detoxification, resolving phlegm, and is commonly used in Chinese and Western medicines such as colds, clearing away heat and detoxification. As the vast majority of artificial bezoar-related preparations are national essential drugs, with the further implementation of the medical reform policy, the downstream industry of artificial bezoar will enter a new round of business cycle. Jianfeng Pharmaceutical has many years of experience in artificial bezoar production. The technological transformation project will use the existing workshop structure, public works and operators of Qiubin Factory to achieve an annual production capacity of 100 tons of artificial bezoar by adding production equipment such as double cone rotary vacuum drying, horizontal ball mill pulverizer unit, hopper and hoist, closed screening system, and upgrading some public systems. According to the project implementation plan, the project will complete the civil engineering in May. Complete the commissioning, testing and verification of equipment and facilities in July, with trial production conditions; Strive to complete the on-site inspection of GMP certification before the end of December. At present, the factory buildings in Qiubin are vacated and the site is cleaned up. It is understood that the production of natural bezoar is very small, the price is extremely high, and the market rarely provides it. As a biochemical API, artificial bezoar has fewer manufacturers. In the past, due to relatively loose supervision, the testing methods of raw materials and finished products are relatively simple, the quality control indicators are not perfect, and the quality of products on the market is uneven. It is imperative to improve the quality standards. To this end, the State Food and Drug Administration issued the "Biochemical Drug GMP Quality Management Practice (Draft for Comment)" at the end of 2016, which was implemented in March 2017. spike medicine
2020
07-31
Recently, Jianfeng Health has been awarded a number of plaques and certificates by the Department of Science and Technology of Zhejiang Province, the people's Government of Jinhua City, and the Science and Technology Bureau of Jinhua City. They are "Zhejiang Science and Technology small and medium-sized Enterprises", "Jinhua High-tech Enterprises", "Jinhua Agricultural Science and Technology Enterprises", "Jinhua Agricultural Science and Technology Research and Development Center" and so on. According to the relevant requirements, Zhejiang science and technology-based small and medium-sized enterprises must be small and medium-sized enterprises with independent intellectual property rights, proprietary technology or advanced knowledge, engaged in the research, development, production, sales and service of high-tech and its products, and the proportion of enterprises engaged in scientific and technological research and development personnel accounting for no less than 10% of the total number of employees in that year. Since its establishment, Jianfeng Health has attached great importance to the training of scientific and technological personnel, paid attention to the application of its own intellectual property rights, paid attention to product research and development and the protection of intellectual property rights, promoted the application of intellectual property rights, and encouraged employees to invent and create. By the end of 2016, a total of 8 invention patents and 5 appearance patents had been applied, and 1 invention patent and 5 appearance patents had been obtained. High-tech enterprises in Jinhua City must meet the requirements of the ''High-tech Fields Supported by the State, ''and continue to carry out research and development and technological achievements transformation. Their main products (services) have independent intellectual property rights (authorized, registered or accepted). There are certain requirements for the proportion of R & D personnel, the proportion of R & D funds and the income of high-tech products. The acquisition of high-tech enterprises in Jinhua City has laid the foundation for the further declaration of national high-tech enterprises in the future. In the identification of agricultural science and technology enterprises in Jinhua City, the field of peak health technology belongs to the deep processing technology and equipment of agricultural products, Chinese herbal pieces and plant extracts.
2020
07-31
Jingmai Airport Test Flight Successfully Runway Cement Spike Manufacturing
On April 7, a Boeing 737-700 aircraft of China Eastern Airlines Yunnan took off from Kunming. After completing two flight test subjects, it landed safely at Lancang Jingmai Airport. This not only marked the basic completion of the airport flight area, The official start of the test flight also marked that the "Peak" brand airport runway cement passed the first "final exam". Lancang Jingmai Airport is a major project with milestone significance in the history of Pu'er transportation construction. Since then, an air corridor connecting southwest Yunnan and Southeast Asia has been added between Kunming and Pu'er, which will greatly promote the development and utilization of tourism resources in Lancang, Menglian and Ximeng "Pu'er Green Triangle" area, and promote the sustainable development of local economy and society; it is of great significance to strengthen the city's national defense construction, maintain border stability, promote national unity, improve emergency rescue capabilities, and promote Pu'er's integration into the country's "Belt and Road" construction. Since the start of the construction of the airport, Yunnan Jianfeng has been paying close attention to it, organizing technical research and repeated tests, and finally produced high-quality airport runway special cement, and with excellent product quality, superior product performance and high-quality service, it has become a runway for Lancang Airport. Cement manufacturer. This not only fills the gap of "peak" airport special cement, but also is of great significance to promote the "peak" brand and improve the market influence of enterprises. It is understood that Jingmai Airport is initially confirmed to be officially opened to traffic at the end of May. (Li Liangping)
2020
07-30
Peak Pharmaceutical was rated as a national intellectual property advantage enterprises
The score ranked first among Jinhua participating enterprises. A few days ago, Peak Pharmaceutical Company was rated as a national intellectual property advantage enterprise. The selection of national intellectual property advantage enterprises is organized by the State Intellectual Property Office. The purpose is to accelerate the formation of a group of Chinese intellectual property leading enterprises with independent intellectual property rights, well-known brands and international competitive advantages, and achieve the development goal of strong intellectual property enterprises. Since Jianfeng Pharmaceutical introduced the GB-T29490-2013 "Enterprise Intellectual Property Management Standard" in 2013, it has been rated as a patent demonstration enterprise in Zhejiang Province in 2013. In 2014, the "Jianfeng" trademark obtained a famous trademark in Zhejiang Province, and the first edition of the "Intellectual Property Manual" was compiled and implemented in 2015. In 2016, it passed the third-party certification of the GB-T29490-2013 "Enterprise Intellectual Property Management Standard". The "Jianfeng" trademark was rated as a well-known trademark by the State Administration of China. In the application and selection of national knowledge by superior enterprises, 52 enterprises in Zhejiang Province won this honor, ranking second in the country in number; Jianfeng Pharmaceutical ranked first among Jinhua participating enterprises. (Zhang Mingyin)
2020
07-31
Group Party Committee to determine the annual work plan
The party Committee of the group company has determined its work ideas and work plan for 2017 a few days ago, and relevant work has been arranged below. In view of the current new political and economic situation and the task of enterprise transformation and development, the general requirements of the Party Committee of the Group Company for 2017 are: to thoroughly study and implement the spirit of the Sixth Plenary Session of the 18th CPC Central Committee and the series of important speeches by General Secretary Xi Jinping, the spirit of the Seventh Party Congress of Jinhua City, to closely revolve around the center of enterprise production, operation and reform and development, and to adhere to scientific development and cross-regional development as the first priority, in order to continue to carry out the study and education of "five stars striving for innovation" and "two learning and one doing", we should highlight the main line of comprehensively and strictly administering the party according to the rules, firmly establish the political consciousness, overall situation consciousness, core consciousness and alignment consciousness of the majority of Party members and cadres, strengthen and improve the party building work in enterprises in the spirit of reform, and strive to improve the scientific, standardized and institutionalized level of Party building work in enterprises, in order to promote the scientific development of the group company, leapfrog development and harmonious development, it provides a strong political, ideological and organizational guarantee. The working idea of the Party Committee of the Group Company in 2017 is to focus on "one center", adhere to "one concept", highlight "three key points" and do a good job in "three constructions". That is: centering on the "one center" of enterprise production, operation and reform and development, we should strive to strengthen the "one concept" of "the organic unity of the party's leadership and the improvement of corporate governance"; to "thoroughly implement the main responsibility of the party committee; continue to carry out the study and education of" two learning and one doing "; and improve the system of party building work" as the "three key points", and focus on "team building and team building
2020
07-31